GO
Loading...

Allergan Inc

More

  • *Dow, S&P 500 coming off record closing highs. NEW YORK, Nov 7- U.S. stocks were little changed on Friday, though the Dow and S&P 500 still inched up to new records as the October payroll report pointed to economic resilience in the face of slowing global demand. "It's hard to not bet on the economy, with the fundamentals looking like a full house: earnings are rock solid,...

  • BOSTON, Nov 7- Valeant Pharmaceuticals International Inc can pay "substantially" more for Allergan Inc and should get a fair shot at buying it, William Ackman, the Botox maker's biggest shareholder, said on Friday. Ackman wrote to Allergan's board the day after the company said it was discussing a merger with another company, widely reported to be Actavis, to fend...

  • BOSTON, Nov 7- Valeant Pharmaceuticals International Inc can pay "substantially" more for Allergan Inc and should get a fair shot at buying it, William Ackman, the Botox maker's biggest shareholder, said on Friday. Ackman said this in a letter to Allergan's board the day after the company said it was discussing a merger with another company, widely reported to be...

  • NEW YORK, Nov 7- U.S. stocks receded from record levels on Friday as investors locked in profits after the October payroll report came in weaker than expected, even as the report pointed to economic resilience in the face of slowing global demand. "It's hard to not bet on the economy, with the fundamentals looking like a full house: earnings are rock solid, we're...

  • NEW YORK, Nov 7- Salix Pharmaceuticals Ltd and mobile gaming company Zynga Inc were among the biggest movers of Friday's premarket session, with the companies holding the top two spots for active Nasdaq names. Both saw heavy trading a day after their results, with Salix plummeting and Zynga advancing. Sources familiar with the matter told Reuters that the...

  • The two companies were close to inking a deal, but Botox maker Allergan balked after its due diligence raised questions over inventory levels, the people said, requesting anonymity because the negotiations were confidential. Earlier on Thursday, Allergan said it was in discussions with another party that a source familiar with the situation identified as...

  • BOSTON, Nov 6- Herbalife Ltd.' s new compliance chief has been on the job for exactly one month and on Thursday the supplements and weight loss company's biggest detractor, billionaire investor William Ackman, gave her pointers on how she might proceed. Herbalife's Nutrition Clubs' training programs, its compensation statements, income claims, sales of...

  • Midday movers: Kate Spade, Apple, Hospira & more Thursday, 6 Nov 2014 | 1:15 PM ET

    Some of Thursday's midday movers:

  • Cramer: What the election means for your money Wednesday, 5 Nov 2014 | 7:20 PM ET

    Not partisan: "Mad Money" host Jim Cramer only cares about your portfolio.

  • Nov 5- The top executive of Actavis Inc, which sources say is pursuing a "white knight" acquisition of Allergan Inc, made a case Wednesday for doing a deal, saying the drug company could continue to grow earnings and manage its debt load. "If there was an opportunity, I think we've demonstrated as a team that if it was the right strategic opportunity with strong...

  • Faber Report: Bill Ackman can vote his shares  Wednesday, 5 Nov 2014 | 9:41 AM ET

    CNBC's David Faber reports Allergan has lost the court battle to prevent Bill Ackman from being able to vote his 9.7 percent stake he owns in the company at the special meeting for shareholders coming in December.

  • Nov 4- A federal judge on Tuesday cleared the way for Pershing Square Capital Management and Valeant Pharmaceuticals International Inc to vote at an Allergan Inc shareholder meeting where they are seeking to remove six of nine Allergan board members as part of a hostile takeover attempt. The companies offered in April to buy Allergan in a cash-and-stock bid...

  • Nov 3- Botox maker Allergan Inc, which is fending off an acquisition by Valeant Pharmaceuticals Inc, said on Monday that it had been approached by another party regarding a potential transaction. Valeant and Pershing Square Capital Management, which owns nearly a 10 percent stake in Allergan, made an offer now worth $55 billion for Allergan at the end of April.

  • Midday movers: Aetna, Geron, Loews & more Monday, 3 Nov 2014 | 12:56 PM ET

    Some of Monday's midday movers:

  • Nov 3- Allergan Inc, which is fending off an acquisition by Valeant Pharmaceuticals Inc, said on Monday that it had been approached by another party regarding a potential transaction. Valeant and Pershing Square Capital Management made an offer, now worth $55 billion, for Allergan at the end of April. Pershing Square owns nearly a 10 percent stake in Allergan.

  • Ackman & Allergan in court  Tuesday, 28 Oct 2014 | 11:18 AM ET

    Investor Bill Ackman is in court today over insider trading allegations in the deal between Allergan and Valeant Pharmaceuticals, reports CNBC's Kate Kelly.

  • Cramer Remix: Keep your Twitter #criticism Monday, 27 Oct 2014 | 7:15 PM ET

    Oil traded down during the day, and Twitter traded down after hours. Here’s what Mad Money host Jim Cramer thinks happens next

  • Takeover drama for your mama: Cramer reveals Monday, 27 Oct 2014 | 6:26 PM ET
    David Pyott, CEO of Allergan, left, with Jim Cramer on Mad Money.

    Jim Cramer sits down with this company CEO to talk about its hostile takeover bid and the drive for independence that brings in more profits

  • BUSINESS-NEWS-SCHEDULE AT 1330 GMT /9.30 AM ET Monday, 27 Oct 2014 | 10:08 AM ET

    MILAN- Italy's Monte dei Paschi di Siena is likely to try to plug a capital shortfall uncovered by Europe- wide stress tests through asset sales and possibly another cash call, but longer term a takeover could be inevitable. LONDON- Europe's banking healthcheck showed countries and lenders are implementing global capital rules at vastly different speeds, and...

  • Allergan CEO on the call  Monday, 27 Oct 2014 | 9:38 AM ET

    CNBC's David Faber reports on comments made by Allergan chairman and CEO David E.I. Pyott on the process of a potential acquisition.